In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

“Dental care is available for all vulnerable communities and we encourage people to obtain information on how to access oral-health care correctly and to avoid any confusion or disappointment,” says ...

When it comes to taking care of our bodies, oral health is often overlooked, especially by men who may not prioritize dental ...

Only one is FDA-approved for hair loss. Topical minoxidil is FDA-approved specifically for the treatment of pattern baldness.

Research shows 86% of women and 94% of men in the U.K. don’t know that changes to their teeth, tongue or gums can be linked ...

In South Africa, gum disease has become a widespread issue, ranking second only to the common cold in prevalence. An ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

My grandmother Goldie died in 1984. Among other things, she had developed dementia and lived with us for several years when ...

Approximately 4 million patients in the United States are currently being treated with DOAC therapy. The review paper, titled ...

The conservative media star said he decided to launch Alp nicotine pouches because Zyn maker Philip Morris couldn’t take a ...

New Drugs on the Horizon to Challenge Novo Nordisk and Eli Lilly Novo Nordisk and Eli Lilly have set the bar for efficacy and ...

Bionpharma Inc. has issued a recall foir a single batch (2310083) of Atovaquone Oral Suspension, 750mg per mL to the consumer ...